nach oben

Rheumatology International

Erschienen in:

28.10.2022 | Systematic Review

Prevalence of hearing loss in patients with Sjögren syndrome: a systematic review and meta-analysis

verfasst von: Vasileios Paraschou, Styliani Partalidou, Pavlos Siolos, Zoi Papadopoulou, Nikolaos Chaitidis

Erschienen in: Rheumatology International | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Sjögren syndrome (SS) is a multisystem autoimmune disease, primarily targeting salivary and lacrimal glands; skin, nasal and vaginal dryness, along with musculoskeletal pain and fatigue are the most commonly reported symptoms. Hearing loss is hypothesized to be frequent as well. The purpose of this systematic review was to estimate the prevalence of Hearing loss and its different subtypes in patients with Sjögren syndrome. PRISMA guidelines were followed to ensure highest quality for our systematic review. A random effects model meta-analysis and meta-regression was conducted using I² as heterogeneity indicator. Eleven observational studies were included in this systematic review. Ten of them were cross-sectional, while one study was case–control. Studies were assessed for risk of bias: all were rated to a moderate level, except for two rated to a low level. Pooled prevalence of any type of hearing loss was 52.2%. After excluding studies rated to moderate bias, the pooled prevalence of hearing loss was 36.7%. We also conducted a subgroup analysis depending on type of hearing loss. Pooled prevalence of sensorineural hearing loss was 42.6%., while pooled prevalence of conductive hearing loss and mixed hearing loss were 5% and 2.3%, respectively. Meta-regression was conducted in an effort to identify possible variables capable to explain high heterogeneity between studies. Sample size and year of study were separately found to account for a portion of heterogeneity between studies of sensorineural hearing loss. Year of study was also found to account for a portion of heterogeneity between studies of conductive hearing loss. In conclusion, sensorineural hearing loss, is highly prevalent in patients with Sjögren syndrome. On this basis, early screening and follow-up of patients with Sjögren syndrome by pure tone audiometry is important.

Qin B, Wang J, Yang Z et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74:1983–1989CrossRef

Mavragani CP, Schini M et al (2012) Brief report: adrenal autoimmunity in primary Sjögren’s syndrome. Arthritis Rheum 64:4066–4071. https://doi.org/10.1002/art.34679CrossRef

Teos LY, Alevizos I (2017) Genetics of Sjögren’s syndrome. Clin Immunol 182:41–47. https://doi.org/10.1016/j.clim.2017.04.018CrossRef

Liu Z, Chu A (2021) Sjögren’s syndrome and viral infections. Rheumatol Ther 8:1051–1059. https://doi.org/10.1007/s40744-021-00334-8CrossRef

Teruel M, Barturen G, Martínez-Bueno M et al (2021) Integrative epigenomics in Sjögren’s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. Sci Rep 11:23292. https://doi.org/10.1038/s41598-021-01324-0CrossRef

Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 9:544–556CrossRef

Brito-Zerón P, Baldini C, Bootsma H et al (2016) Sjögren syndrome. Nat Rev Dis Prim 2:1–20. https://doi.org/10.1038/nrdp.2016.47CrossRef

Sebastian A, Szachowicz A, Wiland P (2019) Classification criteria for secondary Sjögren’s syndrome. Current state of knowledge. Reumatologia 57:277–280CrossRef

van Nimwegen JF, van Ginkel MS et al (2018) Validation of the ACR-EULAR criteria for primary Sjögren’s syndrome in a Dutch prospective diagnostic cohort. Rheumatology (Oxford) 57(5):818–825. https://doi.org/10.1093/rheumatology/kex495CrossRef

10.

Gündüz B, Yildirim N, Güven SC et al (2019) Evaluation of medial olivocochlear efferent system and hearing loss in patients with primary Sjögren’s syndrome. Turk J Med Sci 49:1647–1654. https://doi.org/10.3906/sag-1901-128CrossRef

11.

Hatzopoulos S, Amoroso C, Aimoni C et al (2002) Hearing loss evaluation of Sjogren’s syndrome using distortion product otoacoustic emissions. Acta Otolaryngol 122:20–25. https://doi.org/10.1080/00016480260094929CrossRef

12.

Seeliger T, Bönig L, Witte T et al (2020) Hearing dysfunction in patients with Neuro-Sjögren: a cross-sectional study. Ann Transl Med 8:1069CrossRef

13.

Thanooja CV, Augustine AM, Lepcha A et al (2018) Audiological profile in primary Sjögren’s syndrome in a tertiary care setting and its clinical implications. Indian J Otolaryngol Head Neck Surg 70:59–65. https://doi.org/10.1007/s12070-015-0956-yCrossRef

14.

Gk T, Pv V, Pelechas E et al (2019) Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol 276:2419–2426CrossRef

15.

Dalton DS, Cruickshanks KJ, Klein BEK et al (2003) The impact of hearing loss on quality of life in older adults. Gerontologist 43:661–668. https://doi.org/10.1093/geront/43.5.661CrossRef

16.

Liu CM, Lee CTC (2019) Association of hearing loss with dementia. JAMA Netw Open 2:e198112. https://doi.org/10.1001/jamanetworkopen.2019.8112CrossRef

17.

Michels TC, Duffy MT, Rogers DJ (2019) Hearing loss in adults: differential diagnosis and treatment. Am Fam Physician 100(2):98–108

18.

Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. https://doi.org/10.1136/bmj.g7647CrossRef

19.

Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https://doi.org/10.1136/bmj.i4919CrossRef

20.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRef

21.

Sterne JAC, Sutton AJ, Ioannidis JPA et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. https://doi.org/10.1136/bmj.d4002CrossRef

22.

Doig JA, Whaley K, Dick WC et al (1971) Otolaryngological aspects of Sjögren’s syndrome. Br Med J 4:460–463CrossRef

23.

Galarza-Delgado DA, Villegas Gonzalez MJ, Riega Torres J et al (2018) Early hearing loss detection in rheumatoid arthritis and primary Sjögren syndrome using extended high frequency audiometry. Clin Rheumatol 37:367–373. https://doi.org/10.1007/S10067-017-3959-0CrossRef

24.

Gusmão Fernandesa FL, Guimarãesa AC, Scaramussaa LS et al (2014) Otorhinolaryngological findings in a group of patients with rheumatic diseases. Rev Bras Reumatol 54:172–178

25.

Trott MS, Hughes GB, Calabrese LH et al (1996) Hearing and Sjögren’s syndrome. Ear Nose Throat J 75:666–6668CrossRef

26.

Tsirves GK, Voulgari PV, Pelechas E et al (2019) Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolaryngol 276:2419–2426. https://doi.org/10.1007/s00405-019-05487-5CrossRef

27.

Tumiati B, Casoli P, Parmeggiani A (1997) Hearing loss in the Sjögren syndrome. Ann Intern Med 126:450–453CrossRef

28.

Ziavra N, Politi EN, Kastanioudakis I et al (2000) Hearing loss in Sjögren’s syndrome patients. A comparative study. Clin Exp Rheumatol 18:725–728

29.

Haile LM, Kamenov K, Briant PS et al (2021) Hearing loss prevalence and years lived with disability, 1990–2019: findings from the global burden of disease study 2019. Lancet 397:996–1009. https://doi.org/10.1016/S0140-6736(21)00516-X/ATTACHMENT/A552CF62-9122-4B03-B1AF-AFCE71BE7E9E/MMC1.PDFCrossRef

30.

Goman AM, Lin FR (2016) Prevalence of hearing loss by severity in the United States. Am J Public Health 106:1820–1822. https://doi.org/10.2105/AJPH.2016.303299CrossRef

31.

Emamifar A, Bjoerndal K, Hansen IM (2016) Is hearing impairment associated with rheumatoid arthritis? A review. Open Rheumatol J. https://doi.org/10.2174/1874312901610010026CrossRef

32.

Ahmadzadeh A, Daraei M, Jalessi M et al (2017) Hearing status in patients with rheumatoid arthritis. J Laryngol Otol 131(10):895–899. https://doi.org/10.1017/S0022215117001670CrossRef

33.

Jeong J, Lim H, Lee K et al (2019) High risk of sudden sensorineural hearing loss in several autoimmune diseases according to a population-based national sample cohort study. Audiol Neurotol 24:224–230. https://doi.org/10.1159/000502677CrossRef

34.

Tanaka EA, Barros H, Polanski JF et al (2019) AB0507 hearing loss in systemic lupus erythematosus. Ann Rheum Dis 78:1716–1717. https://doi.org/10.1136/ANNRHEUMDIS-2019-EULAR.5998CrossRef

35.

Abbasi M, Yazdi Z, Kazemifar AM, Bakhsh ZZ (2013) Hearing loss in patients with systemic lupus erythematosus. Glob J Health Sci 5:102–106CrossRef

36.

Talal N, Moutsopoulos HM, Kassan SS (eds) (1987) Sjögren’s syndrome. Springer Berlin Heidelberg, Heidelberg

37.

Fauchais AL, Lambert M, Launay D et al (2004) Antiphospholipid antibodies in primary Sjögren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 13:245–248. https://doi.org/10.1191/0961203304lu1006oaCrossRef

38.

Compadretti GC, Brandolini C, Ignazio T (2005) Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. Ann Otol Rhinol Laryngol 114:214–218. https://doi.org/10.1177/000348940511400308CrossRef

39.

Teixeira F, Moreira I, Silva AM et al (2013) Neurological involvement in primary Sjögren syndrome. Acta Reumatol Port 38:29–36

40.

Delalande S, de Seze J, Fauchais A-L, Hachulla E et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291. https://doi.org/10.1097/01.md.0000141099.53742.16CrossRef

41.

Jourde-Chiche N, Mancini J, Dagher N et al (2012) Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French pharmacovigilance network. Ann Rheum Dis 71:1586–1587CrossRef

42.

Johansson MSK, Arlinger SD (2003) Prevalence of hearing impairment in a population in Sweden. Int Audiol 42:18–28. https://doi.org/10.3109/14992020309056081CrossRef

43.

Rodríguez-Valiente A, Álvarez-Montero Ó, Górriz-Gil C, García-Berrocal JR (2020) Prevalence of presbycusis in an otologically normal population. Acta Otorrinolaringologica 71:175–180. https://doi.org/10.1016/j.otoeng.2019.05.003CrossRef

44.

Nezos A, Mavragani CP (2015) Contribution of genetic factors to Sjögren’s syndrome and Sjögren’s syndrome related lymphomagenesis. J Immunol Res 2015:754825. https://doi.org/10.1155/2015/754825CrossRef

45.

Psillas G, Binos P, Dimas GG, Daniilidis M, Constantinidis J (2021) Human leukocyte antigen (HLA) influence on prognosis of autoimmune hearing loss. Audiol Res 11:31–37. https://doi.org/10.3390/audiolres11010004CrossRef

46.

Papadimitraki ED, Kyrmizakis DE, Kritikos I, Boumpas DT (2004) Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol 22:485–494

Titel: Prevalence of hearing loss in patients with Sjögren syndrome: a systematic review and meta-analysis
verfasst von: Vasileios Paraschou
Styliani Partalidou
Pavlos Siolos
Zoi Papadopoulou
Nikolaos Chaitidis
Publikationsdatum: 28.10.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 2/2023
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-022-05235-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Systematic review of associations between concomitant rheumatoid arthritis and peripheral arterial disease, health-related quality of life and functional capacity

Sjögren's syndrome associated with erosive rheumatoid arthritis alters its prognosis and long-term therapeutic response: a case–control study

“Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis: case report and literature review”

Radiological assessment and surgical management of cervical spine involvement in patients with rheumatoid arthritis

Serum beta-2 microglobulin as a predictor of nephritis, disease activity, and damage score in systemic lupus erythematosus: a cross-sectional study

Bleeding complications in patients on warfarin undergoing joint injection/aspiration: systematic review and meta-analysis